SNCA

Diseases

• Parkinson disease13 trials
• Lewy body dementia3 trials

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

• Publication

  Molecular determinants of α-synuclein toxicity and aggregation revealed by deep mutagenesis.

  25 Nov 2026· Biochemical Society transactions· PUBMED

• Publication

  New hemiaminal ether dihydropyrimidinones as CK1/CK2 inhibitors targeting α-synuclein in Parkinson's disease.

  2 Nov 2026· RSC advances· PUBMED

• Publication

  Protein adduction by multiple aldehydes contributes to α-synuclein aggregation and dopaminergic neuron loss in rat models of Parkinson's disease.

  2 Nov 2026· Redox biology· PUBMED

• Publication

  Iron affects association and dissociation rates of α-synuclein iron-responsive element mRNA binding to iron regulatory protein in Parkinson's disease.

  31 Oct 2026· International journal of biological macromolecules· PUBMED

• Publication

  Distinct mitochondrial states modulate α-synuclein toxicity.

  26 Oct 2026· Molecular biology of the cell· PUBMED

• Preprint

  Cerebrospinal fluid α-synuclein seed amplification assay positivity identifies a prognostically distinct subgroup in amyotrophic lateral sclerosis.

  26 Oct 2026· medRxiv : the preprint server for health sciences· PUBMED

• Publication

  Serratol, a cembrane diterpene from Boswellia serrata attenuates α-synuclein and fibrillar amyloid-β aggregation in Caenorhabditis elegans.

  23 Oct 2026· Journal of ethnopharmacology· PUBMED

• Publication

  High-altitude environments elevate central and peripheral α-synuclein levels and accelerate PD-related pathology.

  21 Oct 2026· Journal of translational medicine· PUBMED

• Publication

  Cerebrospinal fluid and dural accumulation of α-synuclein impairs CNS clearance in Parkinson's disease.

  20 Oct 2026· The Journal of experimental medicine· PUBMED

• Publication

  Discovery of benzoxazole derivatives as novel α-synuclein aggregate ligands with potential for PET tracer development.

  20 Oct 2026· European journal of medicinal chemistry· PUBMED

• Publication

  The morphology of α-synuclein fibrils changes during formation, storage, and upon exposure to ligands.

  19 Oct 2026· Organic & biomolecular chemistry· PUBMED

• Publication

  Disarming CH25H to clear α-synuclein.

  14 Oct 2026· Trends in molecular medicine· PUBMED

• Publication

  Modulators selectively reshape α-synuclein phase transitions.

  14 Oct 2026· The Journal of chemical physics· PUBMED

• Publication

  Extracellular vesicle α-synuclein topology reveals disease-associated conformers in brain and blood.

  14 Oct 2026· Brain : a journal of neurology· PUBMED

• Publication

  Severe Parkinson's Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report.

  14 Oct 2026· Movement disorders : official journal of the Movement Disorder Society· PUBMED

• Publication

  Elevated erythrocyte membrane pS42-α-synuclein in Parkinson's disease and its changes following plasma cross-incubation.

  14 Oct 2026· Parkinsonism & related disorders· PUBMED

• Publication

  Dibucaine induces autophagic flux and reduces Ser129-phosphorylated α-synuclein in induced pluripotent stem cell-derived neurons with SNCA duplication.

  8 Oct 2026· Frontiers in neurology· PUBMED

• Publication

  Human microglia clear intraneuronal α-synuclein aggregates by GPNMB-mediated trogocytosis.

  7 Oct 2026· Science translational medicine· PUBMED

• Publication

  Amyloid, p-tau, neurofilament light, and α-synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease.

  6 Oct 2026· Alzheimer's & dementia (Amsterdam, Netherlands)· PUBMED

• Publication

  Clinical and biomarker predictors of α-synuclein seeding in cognitive impairment and motor parkinsonism.

  4 Oct 2026· Parkinsonism & related disorders· PUBMED

• Publication

  Astrocytic cathepsin D promotes α-synuclein processing and Lewy neurite-like aggregate maturation.

  2 Oct 2026· EMBO reports· PUBMED

• Trial

  Prevent Cognitive Decline in GBA-associated Parkinson's Disease

  1 Oct 2026· PHASE2 · RECRUITING· CTGOV

• Publication

  α-synuclein pathology drives region-specific tau deposition.

  1 Oct 2026· Alzheimer's & dementia : the journal of the Alzheimer's Association· PUBMED

• Publication

  Full-length brain-derived α-synuclein fibril models reveal fuzzy-coat control of peptide recognition.

  1 Oct 2026· Protein science : a publication of the Protein Society· PUBMED

• Publication

  Visualizing α-synuclein pathology in live brain: A new platform for Parkinson's disease research.

  1 Oct 2026· Clinical and translational medicine· PUBMED

• Publication

  High-resolution genomic architecture of a 1.71-Mb inverted SNCA triplication in a patient-derived PARK4 model.

  30 Sept 2026· Biochemical and biophysical research communications· PUBMED

• Publication

  Crosstalk between exosomes and cellular senescence: A core vicious loop promoting α-synuclein pathology in Parkinson's disease.

  30 Sept 2026· Neural regeneration research· PUBMED

• Publication

  Condensate-driven triglyceride reduction links α-synuclein to mitochondrial dysfunction.

  29 Sept 2026· EMBO reports· PUBMED

• Publication

  Targeting CH25H restores p62-mediated α-synuclein clearance.

  28 Sept 2026· Trends in pharmacological sciences· PUBMED

• Publication

  Sephin1 directly targets PHB2 to activate PINK1-PRKN-dependent mitophagy and alleviate α-synuclein neurotoxicity in Parkinson's disease models.

  25 Sept 2026· Biochemical pharmacology· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.